BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

574 related articles for article (PubMed ID: 27773749)

  • 21. Dose-Dependent AMPK-Dependent and Independent Mechanisms of Berberine and Metformin Inhibition of mTORC1, ERK, DNA Synthesis and Proliferation in Pancreatic Cancer Cells.
    Ming M; Sinnett-Smith J; Wang J; Soares HP; Young SH; Eibl G; Rozengurt E
    PLoS One; 2014; 9(12):e114573. PubMed ID: 25493642
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression.
    Froeling FE; Feig C; Chelala C; Dobson R; Mein CE; Tuveson DA; Clevers H; Hart IR; Kocher HM
    Gastroenterology; 2011 Oct; 141(4):1486-97, 1497.e1-14. PubMed ID: 21704588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer.
    Venkatasubbarao K; Peterson L; Zhao S; Hill P; Cao L; Zhou Q; Nawrocki ST; Freeman JW
    Mol Cancer; 2013 Sep; 12(1):104. PubMed ID: 24025152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intratumoral heterogeneity of the therapeutical response to gemcitabine and metformin.
    Zechner D; Bürtin F; Albert AC; Zhang X; Kumstel S; Schönrogge M; Graffunder J; Shih HY; Müller S; Radecke T; Jaster R; Vollmar B
    Oncotarget; 2016 Aug; 7(35):56395-56407. PubMed ID: 27486761
    [TBL] [Abstract][Full Text] [Related]  

  • 25. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer.
    Liu C; Shi J; Li Q; Li Z; Lou C; Zhao Q; Zhu Y; Zhan F; Lian J; Wang B; Guan X; Fang L; Li Z; Wang Y; Zhou B; Yao Y; Zhang Y
    Clin Sci (Lond); 2019 Mar; 133(5):645-663. PubMed ID: 30782607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of oncogenic Pim-3 kinase modulates transformed growth and chemosensitizes pancreatic cancer cells to gemcitabine.
    Xu D; Cobb MG; Gavilano L; Witherspoon SM; Williams D; White CD; Taverna P; Bednarski BK; Kim HJ; Baldwin AS; Baines AT
    Cancer Biol Ther; 2013 Jun; 14(6):492-501. PubMed ID: 23760491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deoxycytidine Release from Pancreatic Stellate Cells Promotes Gemcitabine Resistance.
    Dalin S; Sullivan MR; Lau AN; Grauman-Boss B; Mueller HS; Kreidl E; Fenoglio S; Luengo A; Lees JA; Vander Heiden MG; Lauffenburger DA; Hemann MT
    Cancer Res; 2019 Nov; 79(22):5723-5733. PubMed ID: 31484670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer.
    Zhang L; Yao J; Li W; Zhang C
    Oncol Res; 2018 Jul; 26(6):827-835. PubMed ID: 28477403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppression of stromal-derived Dickkopf-3 (DKK3) inhibits tumor progression and prolongs survival in pancreatic ductal adenocarcinoma.
    Zhou L; Husted H; Moore T; Lu M; Deng D; Liu Y; Ramachandran V; Arumugam T; Niehrs C; Wang H; Chiao P; Ling J; Curran MA; Maitra A; Hung MC; Lee JE; Logsdon CD; Hwang RF
    Sci Transl Med; 2018 Oct; 10(464):. PubMed ID: 30355799
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.
    Lee JE; Kang YW; Jung KH; Son MK; Shin SM; Kim JS; Kim SJ; Fang Z; Yan HH; Park JH; Yoon YC; Han B; Cheon MJ; Woo MG; Seo MS; Lim JH; Kim YS; Hong SS
    Cancer Lett; 2021 Jun; 507():97-111. PubMed ID: 33744388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma.
    Borsoi C; Leonard F; Lee Y; Zaid M; Elganainy D; Alexander JF; Kai M; Liu YT; Kang Y; Liu X; Koay EJ; Ferrari M; Godin B; Yokoi K
    Cancer Lett; 2017 Sep; 403():296-304. PubMed ID: 28687352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2.
    Dangi-Garimella S; Krantz SB; Barron MR; Shields MA; Heiferman MJ; Grippo PJ; Bentrem DJ; Munshi HG
    Cancer Res; 2011 Feb; 71(3):1019-28. PubMed ID: 21148071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined Use of Metformin and Everolimus Is Synergistic in the Treatment of Breast Cancer Cells.
    Wang Y; Wei J; Li L; Fan C; Sun Y
    Oncol Res; 2014; 22(4):193-201. PubMed ID: 26351208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer.
    Kuninty PR; Bansal R; De Geus SWL; Mardhian DF; Schnittert J; van Baarlen J; Storm G; Bijlsma MF; van Laarhoven HW; Metselaar JM; Kuppen PJK; Vahrmeijer AL; Östman A; Sier CFM; Prakash J
    Sci Adv; 2019 Sep; 5(9):eaax2770. PubMed ID: 31517053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer.
    Dosch AR; Dai X; Reyzer ML; Mehra S; Srinivasan S; Willobee BA; Kwon D; Kashikar N; Caprioli R; Merchant NB; Nagathihalli NS
    Mol Cancer Res; 2020 Apr; 18(4):623-631. PubMed ID: 31949002
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
    Suzuki K; Takeuchi O; Suzuki Y; Kitagawa Y
    Int J Oncol; 2019 Feb; 54(2):764-772. PubMed ID: 30570108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MK8722, an AMPK activator, inhibiting carcinoma proliferation, invasion and migration in human pancreatic cancer cells.
    Wang C; Huang B; Sun L; Wang X; Zhou B; Tang H; Geng W
    Biomed Pharmacother; 2021 Dec; 144():112325. PubMed ID: 34656065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel DDIT3 activator dehydroevodiamine effectively inhibits tumor growth and tumor cell stemness in pancreatic cancer.
    Zhu SL; Qi M; Chen MT; Lin JP; Huang HF; Deng LJ; Zhou XW
    Phytomedicine; 2024 Jun; 128():155377. PubMed ID: 38503154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.
    Wang YH; Sui YN; Yan K; Wang LS; Wang F; Zhou JH
    Oncol Rep; 2015 Apr; 33(4):1699-706. PubMed ID: 25647019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.